JB Chemicals & Pharmaceuticals plunged by over 18% in intra-day on the bourses today after the drug-maker entered into a deal to sell its over-the-counter (OTC) business in Russia and CIS countries to Johnson & Johnson subsidiary Cilag GmbH.
Following the move, shares of the company slumped by 18.29% to touch a one-month low of Rs 118.55 on the BSE during intra-day trade.
On the NSE, the stock nosedived by 17.76% to an intra-day low of Rs 119.
Investors became worried that the sale of the Russian business will impact future revenues of the firm and opted for heavy selling, an analyst said.
The Mumbai-based firm entered into an agreement with Cilag GmbH to sell its OTC business in Russia and CIS countries for a consideration of Rs 938.51 crore.
The Russia/CIS (Commonwealth of Independent States) OTC business is being sold as a going concern on a slump sale basis, including trademarks, brand, patents, registrations and domain names, the company said.
Meanwhile, the BSE Sensex was trading higher by 98.74 points at 18,092.07 at 1316 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
